Training the next generation of scientists and physician-scientists is of the utmost priority in our laboratory. Our alumni have progressed to faculty positions at prominent institutions. Please e-mail us if you are interested in joining our team.
Graduate students: we currently have one open position for a graduate students.
Masters students: we currently have one open position for a masters student.
Medical students: we are currently accepting medical students for focused research projects.
Post-baccalaureate: we are currently accepting applications to the neuropathology brain bank.
Undergraduate and high school: we not are currently not accepting new students at this time.
Clinical, histopathological, biochemical and genetic studies of primary age-related tauopathy (R01NS095252)
Regulation of tau expression in Alzheimer's disease and aging (R01AG054008)
Clinicopathological studies of chronic traumatic encephalopathy (R01AG062348)
Clinicopathological studies of age-related neurodegeneration in HIV/AIDS (RF1AG060961)
Dr. Crary studied neuroscience at Brown University and conducted is neuropathology training at Columbia University Medical Center ...
OUR RESEARCH FOCUSES ON THE DRIVERS AND MECHANISMS OF NEUROFIBRILLARY TANGLE FORMATION AND TOXICITY IN NEURODEGENERATIVE DISORDERS. WE ARE USING STATE-OF-THE-ART BIOCHEMICAL, MOLECULAR, AND GENETIC APPROACHES TO UNLOCK THE SECRETS OF DEVASTATING BRAIN DISEASES
Our research focuses on the molecular neuropathology of neurodegenerative diseases. Using an interdisciplinary approach, we are unravelling the molecular changes occurring in diseases with neurofibrillary tangles composed of the tau protein (i.e., tauopathies). This diverse set of brain diseases includes dementias, such as Alzheimer's disease, movement disorders, such as Parkinson's disease and related conditions, and the long-term sequelae of repetitive traumatic brain injury, or chronic traumatic encephalopathy. We are using histological, genetic, biochemical and molecular approaches to pinpoint underlying molecular and cellular triggers of these diseases. Recently, we have begun to deploy powerful artificial intelligence (machine learning)-based approaches, including computer vision, which is revolutionizing our approach to neurodegeneration.